Genetic and Epigenetic Regulation of Valvulogenesis: Implications for Congenital and Degenerative Valve Disease

Determining the molecular causes of congenital and degenerative valve illnesses requires a knowledge of the intricate process of heart valve creation, or valvulogenesis, which is controlled by a network of genetic and epigenetic variables. The genetic and epigenetic processes that contribute to the formation of heart valves are examined in this study, with an emphasis on their implications for the pathophysiology of illness and possible treatment approaches. Using databases including PubMed, Scopus, and Google Scholar, a thorough literature search was carried out using keywords such as “vasculogenesis,” “genetic regulation,” “epigenetics,” and “valve disease.” Key research publications, clinical trials, and data from model organisms were reviewed to pick studies from 2000 to 2024 that focused on genetic and epigenetic control in heart valve development. Important genes (including GATA4, Notch, and transforming growth factor beta) and epigenetic regulators (such as DNA methylation and long non-coding RNAs) implicated in valvulogenesis have been discovered recently. Degenerative conditions like aortic stenosis and congenital valve abnormalities such as bicuspid aortic valve and mitral valve prolapse are associated with dysregulation of these pathways. Understanding the role of genetic and epigenetic control in vasculogenesis opens up exciting possibilities for treatment strategies. Improved patient outcomes in congenital and degenerative valve disease may result from future studies that concentrate on epigenetic changes, gene therapy, and innovative diagnostic methods.